Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 57 |
| Active Pipeline (Recruiting Now) | 24 (12) |
| Completed vs Stopped Early | 15 / 18 (31.6%) |
| Median Closed Actual Enrollment | 23 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Columbia University Irving Medical Center | New York, NY | 48 |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 4 |
| Weill Cornell Medicine | New York, NY | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03121209 | Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H) | Phase III | COMPLETED |
| NCT03192215 | AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Columbia University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.